Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 9/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 6/20 | 0.44 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787110 | 0.92 | ADK (0.52) | ADKSLC29A1SRCLCKTEK | |
| SCHEMBL20351758 | 0.89 | ADK (0.54) | ADKSLC29A1RETMTORRAB9A | |
| SCHEMBL16236390 | 0.84 | ADK (0.54) | ADKSLC29A1SRCLCKKDR | |
| SCHEMBL29484542 | 0.84 | ADK (0.54) | ADKSLC29A1SRCLCKKDR | |
| SCHEMBL20351619 | 0.84 | ADK (0.51) | ADKSRCLCKTEKKDR | |
| SCHEMBL1939761 | 0.82 | ADK (0.52) | ADKSLC29A1SRCLCKTEK | |
| SCHEMBL401328 | 0.82 | ADK (0.52) | ADKSLC29A1SRCLCKKDR | |
| SCHEMBL16236685 | 0.81 | ADK (0.51) | ADKSLC29A1SRCLCKTEK | |
| SCHEMBL22086530 | 0.81 | ADK (0.51) | ADKSLC29A1SRCLCKTEK | |
| SCHEMBL30373169 | 0.81 | ADK (0.51) | ADKSLC29A1SRCLCKTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683629-B | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-113683629-A | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-110036014-B | Compound with AXL inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-09-07 | — | — | CN | disclosed |
| WO-2018121228-A1 | COMPOUND HAVING AXL INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2018-07-05 | — | — | WO | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| WO-2004100868-A2 | METHOD OF TREATING TRANSPLANT REJECTION | ABBOTT LABORATORIES (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | ADK 2215/4885SLC29A1 3890/4885SRC 46/4885 |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | ADK 1047/4885SLC29A1 700/4885SRC 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.